Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

1.890 -0.180 (-8.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 143,607
Open 2.060
Bid (Size) 1.890 (1)
Ask (Size) 2.020 (11)
Prev. Close 2.070
Today's Range 1.890 - 2.080
52wk Range 1.150 - 3.160
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
From ChromaDex Corporation
Via Business Wire

Performance

YTD
+11.83%
+11.83%
1 Month
-1.56%
-1.56%
3 Month
-12.50%
-12.50%
6 Month
-5.03%
-5.03%
1 Year
-26.46%
-26.46%

More News

Read More
This Analyst Cuts ChromaDex's Price Target On Revised Growth Trajectory
Via Benzinga
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
From ChromaDex Corporation
Via Business Wire
ChromaDex Named Brianna Gerber Chief Financial Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
From ChromaDex Corporation
Via Business Wire
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
From ChromaDex Corporation
Via Business Wire
$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
From ChromaDex Corporation
Via Business Wire
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
From ChromaDex Corporation
Via Business Wire
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
From ChromaDex Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
Via Benzinga
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
From ChromaDex Corporation
Via Business Wire
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
From ChromaDex Corporation
Via Business Wire
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Via Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.